Research Article
Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets
Table 7
Composition of 19 formulations based on the central composite design.
| | Formulation code | Point type | Independent variables | | PEG 6000 (%) | Crospovidone (%) | Compression force (kN) |
| | Fd1 | Axial | 4.5(0) | 6(0) | 18.41(+α) | | Fd2 | Center | 4.5(0) | 6(0) | 10(0) | | Fd3 | Factorial | 2(−1) | 2(−1) | 5(−1) | | Fd4 | Center | 4.5(0) | 6(0) | 10(0) | | Fd5 | Factorial | 7(+1) | 2(−1) | 5(−1) | | Fd6 | Factorial | 2(−1) | 10(+1) | 15(+1) | | Fd7 | Axial | 4.5(0) | 6(0) | 1.59 α | | Fd8 | Factorial | 2(−1) | 2(−1) | 15(+1) | | Fd9 | Factorial | 2(−1) | 10(+1) | 5(−1) | | Fd10 | Factorial | 7(+1) | 2(−1) | 15(+1) | | Fd11 | Axial | 4.5(0) | 12.7(+α) | 10(0) | | Fd12 | Center | 4.5(0) | 6(0) | 10(0) | | Fd13 | Factorial | 7(+1) | 10(+1) | 15(+1) | | Fd14 | Axial | 8.7 (+α) | 6(0) | 10(0) | | Fd15 | Axial | 4.7(0) | 2(−α) | 10(0) | | Fd16 | Axial | 0.296(−α) | 6(0) | 10(0) | | Fd17 | Center | 4.5(0) | 6(0) | 10(0) | | Fd18 | Center | 4.5(0) | 6(0) | 10(0) | | Fd19 | Factorial | 7(+1) | 10(+1) | 5(−1) |
|
|
Fd = formulation design based on the CCD.
|
